NYSE:AORT Artivion (AORT) Stock Forecast, Price & News $15.04 -0.02 (-0.13%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$14.97▼$15.2550-Day Range$14.80▼$17.5252-Week Range$9.64▼$18.00Volume102,260 shsAverage Volume228,011 shsMarket Capitalization$617.24 millionP/E RatioN/ADividend YieldN/APrice Target$23.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Artivion MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside54.6% Upside$23.25 Price TargetShort InterestBearish7.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth221.43%From $0.14 to $0.45 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.90 out of 5 starsMedical Sector689th out of 965 stocksSurgical & Medical Instruments Industry73rd out of 94 stocks 3.4 Analyst's Opinion Consensus RatingArtivion has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.25, Artivion has a forecasted upside of 54.6% from its current price of $15.04.Amount of Analyst CoverageArtivion has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.29% of the float of Artivion has been sold short.Short Interest Ratio / Days to CoverArtivion has a short interest ratio ("days to cover") of 14.6, which indicates bearish sentiment.Change versus previous monthShort interest in Artivion has recently decreased by 2.74%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArtivion does not currently pay a dividend.Dividend GrowthArtivion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AORT. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Artivion this week, compared to 1 article on an average week.Search Interest7 people have searched for AORT on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Artivion to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Artivion insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of Artivion is held by insiders.Percentage Held by Institutions83.32% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Artivion are expected to grow by 221.43% in the coming year, from $0.14 to $0.45 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artivion is -21.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artivion is -21.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtivion has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Artivion (NYSE:AORT) StockArtivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent and graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.Read More AORT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AORT Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comFinancial Contrast: Surmodics (NASDAQ:SRDX) & Artivion (NYSE:AORT)August 31, 2023 | finance.yahoo.comWall Street Analysts Believe Artivion (AORT) Could Rally 44.41%: Here's is How to TradeSeptember 23, 2023 | Stansberry Research (Ad)U.S. "Shadow Banks" About to Blow up again?Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.August 10, 2023 | finance.yahoo.comDoes Artivion (AORT) Have the Potential to Rally 52.78% as Wall Street Analysts Expect?August 3, 2023 | msn.comArtivion (AORT) Q2 Earnings and Revenues Top EstimatesAugust 3, 2023 | finance.yahoo.comArtivion Reports Second Quarter 2023 Financial ResultsAugust 2, 2023 | benzinga.comEarnings Preview: ArtivionJuly 28, 2023 | finance.yahoo.comThe Return Trends At Artivion (NYSE:AORT) Look PromisingSeptember 23, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.July 20, 2023 | finance.yahoo.comArtivion Announces Release Date and Teleconference Call Details for Second Quarter 2023 Financial ResultsJuly 20, 2023 | msn.comArtivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)July 2, 2023 | finance.yahoo.comAfter losing 11% in the past year, Artivion, Inc. (NYSE:AORT) institutional owners must be relieved by the recent gainJune 8, 2023 | finance.yahoo.comArtivion, Inc. (NYSE:AORT) Could Be Riskier Than It LooksMay 23, 2023 | markets.businessinsider.comArtivion To Receive Milestone Payment From Baxter On FDA PMA Approval For PerClotMay 23, 2023 | msn.comArtivion wins FDA nod for Baxter-partnered clotting productMay 8, 2023 | msn.comMorgan Stanley Maintains Artivion (AORT) Equal-Weight RecommendationMay 5, 2023 | msn.comNeedham Maintains Artivion (AORT) Buy RecommendationMay 4, 2023 | msn.comArtivion: Q1 Earnings InsightsMay 4, 2023 | finance.yahoo.comArtivion (AORT) Q1 Earnings and Revenues Beat EstimatesMay 4, 2023 | finance.yahoo.comArtivion Reports First Quarter 2023 Financial ResultsApril 22, 2023 | benzinga.comArtivion Stock (NYSE:AORT), DividendsApril 20, 2023 | finance.yahoo.comArtivion Announces Release Date and Teleconference Call Details for First Quarter 2023 Financial ResultsApril 20, 2023 | seekingalpha.comArtivion: Reaffirm Hold As Pressures To Growth RemainApril 10, 2023 | finance.yahoo.comArtivion to Participate in the 22nd Annual Needham Virtual Healthcare ConferenceMarch 31, 2023 | finance.yahoo.comShareholders in Artivion (NYSE:AORT) are in the red if they invested a year agoMarch 6, 2023 | finance.yahoo.comArtivion to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceMarch 2, 2023 | benzinga.comMassive Insider Trade At ArtivionSee More Headlines Receive AORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter. Email Address AORT Company Calendar Last Earnings8/03/2023Today9/23/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:AORT CUSIPN/A CIK784199 Webwww.cryolife.com Phone(770) 419-3355Fax770-426-0031Employees1,300Year FoundedN/APrice Target and Rating Average Stock Price Forecast$23.25 High Stock Price Forecast$28.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+54.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E Ratio107.43 P/E GrowthN/ANet Income$-19,190,000.00 Net Margins-8.66% Pretax Margin-6.34% Return on Equity1.97% Return on Assets0.71% Debt Debt-to-Equity Ratio1.10 Current Ratio4.69 Quick Ratio3.30 Sales & Book Value Annual Sales$313.79 million Price / Sales1.97 Cash Flow$0.61 per share Price / Cash Flow24.61 Book Value$7.05 per share Price / Book2.13Miscellaneous Outstanding Shares41,040,000Free Float38,331,000Market Cap$617.24 million OptionableOptionable Beta1.39 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. James Patrick Mackin (Age 56)Chairman, Pres & CEO Comp: $1.63MMr. David Ashley Lee CPA (Age 58)CPA, Exec. VP, COO & CFO Comp: $825.43kMs. Jean F. Holloway Esq. (Age 66)Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. Comp: $636.72kMr. John E. Davis (Age 58)Sr. VP of Global Sales & Marketing Comp: $609.91kDr. Marshall S. Stanton M.D. (Age 66)Sr. VP of Clinical Research & Chief Medical Officer Comp: $615.55kMs. Amy D. Horton CPA (Age 53)CPA, VP & Chief Accounting Officer Mr. Matthew A. Getz (Age 53)VP & Chief HR Officer Robert C. ThomsonVP of R&DMr. Florian TyrsVP of Global Operations & GM of HechingenMore ExecutivesKey CompetitorsSilk Road MedicalNASDAQ:SILKIRadimedNASDAQ:IRMDNevroNYSE:NVROSurmodicsNASDAQ:SRDXOrthofix MedicalNASDAQ:OFIXView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCSold 154,508 shares on 8/24/2023Ownership: 2.269%California State Teachers Retirement SystemSold 4,434 shares on 8/21/2023Ownership: 0.111%Nuveen Asset Management LLCBought 17,744 shares on 8/16/2023Ownership: 0.595%Royal Bank of CanadaSold 1,891 shares on 8/15/2023Ownership: 0.034%Citadel Advisors LLCSold 1,000 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AORT Stock - Frequently Asked Questions Should I buy or sell Artivion stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Artivion in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AORT shares. View AORT analyst ratings or view top-rated stocks. What is Artivion's stock price forecast for 2023? 4 Wall Street analysts have issued 1 year price objectives for Artivion's shares. Their AORT share price forecasts range from $14.00 to $28.00. On average, they expect the company's share price to reach $23.25 in the next year. This suggests a possible upside of 54.6% from the stock's current price. View analysts price targets for AORT or view top-rated stocks among Wall Street analysts. How have AORT shares performed in 2023? Artivion's stock was trading at $12.12 at the start of the year. Since then, AORT shares have increased by 24.1% and is now trading at $15.04. View the best growth stocks for 2023 here. When is Artivion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our AORT earnings forecast. How were Artivion's earnings last quarter? Artivion, Inc. (NYSE:AORT) issued its quarterly earnings data on Thursday, August, 3rd. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.01 by $0.05. The firm had revenue of $89.25 million for the quarter, compared to analyst estimates of $84.45 million. Artivion had a positive trailing twelve-month return on equity of 1.97% and a negative net margin of 8.66%. What guidance has Artivion issued on next quarter's earnings? Artivion issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $342.00 million-$350.00 million, compared to the consensus revenue estimate of $340.69 million. What is Artivion's stock symbol? Artivion trades on the New York Stock Exchange (NYSE) under the ticker symbol "AORT." Who are Artivion's major shareholders? Artivion's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (17.26%), State Street Corp (3.92%), Dimensional Fund Advisors LP (3.56%), Royce & Associates LP (2.32%), Perceptive Advisors LLC (2.27%) and Wasatch Advisors LP (1.98%). Insiders that own company stock include Amy Horton, Andrew M Green, David Ashley Lee, Dennis B Maier, James P Mackin, Matthew A Getz and Rochelle L Maney. View institutional ownership trends. How do I buy shares of Artivion? Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Artivion's stock price today? One share of AORT stock can currently be purchased for approximately $15.04. How much money does Artivion make? Artivion (NYSE:AORT) has a market capitalization of $617.24 million and generates $313.79 million in revenue each year. The company earns $-19,190,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. How many employees does Artivion have? The company employs 1,300 workers across the globe. How can I contact Artivion? Artivion's mailing address is 1655 Roberts Blvd NW, Kennesaw, Georgia 30144-3632. The official website for the company is www.cryolife.com. The company can be reached via phone at (770) 419-3355, via email at investors@cryolife.com, or via fax at 770-426-0031. This page (NYSE:AORT) was last updated on 9/23/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artivion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.